Theseus Pharmaceuticals, Inc. terminated the employment of Timothy P. Clackson, Ph.D. as President of the Company, effective as of December 7, 2023, without cause. In connection with the termination, Dr. Clackson resigned from his positio n as a member of the Board of Directors of the Company, effective as of the Separation Date. As part of the reduction in workforce, the Company also terminated the employment of David Kerstein, M.D. as the Chief Medical Officer of the Company, effective as of the Separation Date, without cause.

On December 1, 2023, the Board appointed Bradford D. Dahms, the Company?s current Chief Financial Officer, President of the Company and as a member of the Board of Directors, effective as of the Separation Date. Mr. Dahms will serve as a Class III director until the annual meeting of stockholders held in 2024 or until his successor is duly elected and qualified. Mr. Dahms will continue to serve as the Company?s Chief Financial Officer, in addition to his role as a director and President.

Mr. Dahms has served as the Company?s Chief Financial Officer since May 2021. From September 2019 to May 2021, Mr. Dahms served as Chief Financial Officer of Selecta Biosciences Inc. Prior to joining Selecta, Mr. Dahms served as Senior Vice President???Healthcare Investment Banking at Cantor Fitzgerald & Co., an investment bank, from April 2014 to August 2019. He also served as an analyst at RBC Capital Markets from 2012 to 2014, and at JPMorgan Chase & Co.

from 2010 to 2012. Mr. Dahms holds a Bachelor of Science degree in Economics from The Ohio State University.